BSE - Delayed Quote INR

Windlas Biotech Limited (WINDLAS.BO)

919.30
-5.30
(-0.57%)
At close: June 4 at 3:29:45 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
7,263,870
--
6,288,850
5,105,810
4,633,730
Cost of Revenue
4,538,180
--
3,961,750
3,254,470
3,028,160
Gross Profit
2,725,690
--
2,327,100
1,851,340
1,605,570
Operating Expense
2,051,910
--
1,679,820
1,372,100
1,199,680
Operating Income
673,780
--
647,280
479,240
405,890
Net Non Operating Interest Income Expense
-13,630
--
8,640
27,020
28,680
Pretax Income
815,670
--
770,910
570,390
455,650
Tax Provision
198,610
--
189,040
144,130
74,760
Net Income Common Stockholders
617,060
--
581,870
426,260
380,890
Diluted NI Available to Com Stockholders
609,940
--
581,870
426,260
380,890
Basic EPS
29.59
--
27.97
19.70
18.58
Diluted EPS
29.29
--
27.88
19.70
18.58
Basic Average Shares
20,858.31
--
20,806.29
21,635.92
20,497.17
Diluted Average Shares
21,079.35
--
20,872.75
21,635.92
20,497.17
Rent Expense Supplemental
--
--
4,850
3,920
4,380
Total Expenses
--
--
5,641,570
4,626,570
4,227,840
Net Income from Continuing & Discontinued Operation
609,940
--
581,870
426,260
380,890
Normalized Income
535,153
--
500,149.61
384,440.35
367,899.70
Interest Income
--
--
19,690
34,900
42,850
Interest Expense
33,320
--
11,050
7,880
14,170
Net Interest Income
-13,630
--
8,640
27,020
28,680
EBIT
848,990
--
781,960
578,270
469,820
EBITDA
--
--
916,400
701,910
591,290
Reconciled Cost of Revenue
4,538,180
--
3,961,750
3,254,470
3,028,160
Reconciled Depreciation
231,860
--
134,440
123,640
121,470
Net Income from Continuing Operation Net Minority Interest
617,060
--
581,870
426,260
380,890
Total Unusual Items Excluding Goodwill
108,270
--
108,270
55,960
15,540
Total Unusual Items
108,270
--
108,270
55,960
15,540
Normalized EBITDA
972,580
--
808,130
645,950
575,750
Tax Rate for Calcs
0
--
0
0
0
Tax Effect of Unusual Items
--
--
26,549.61
14,140.35
2,549.70
3/31/2022 - 8/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANG.BO ANG Lifesciences India Limited
28.62
+0.70%
 
FDC.NS FDC Limited
437.60
-1.00%
 
RPGLIFE.NS RPG Life Sciences Limited
2,165.20
-0.56%
 
NEULANDLAB.NS Neuland Laboratories Limited
11,793.00
-0.22%
 
LAURUSLABS.NS Laurus Labs Limited
623.35
+0.61%
 
PPLPHARMA.NS Piramal Pharma Limited
205.94
+1.07%
 
BIOA BioAge Labs, Inc.
4.2700
+7.02%
 
RGC Regencell Bioscience Holdings Limited
630.10
+3.45%